Recent News

• 02.10.2026 - RenovoRx Establishes RenovoCath® Medical Advisory Board
• 02.05.2026 - RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer
• 02.04.2026 - RenovoRx Announces Clinical Data Supporting the TAMP™ Therapy Platform will be Presented at the SIO 2026 Annual Scientific Meeting
• 01.28.2026 - RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Oncology Annual Scientific Meeting
• 01.20.2026 - RenovoRx Expands RenovoCath® Commercial Adoption to Nine Active Cancer Centers Including City of Hope Cancer Center and Moffitt Cancer Center
• 01.14.2026 - RenovoRx to Participate in AlphaNorth Capital Event, January 16-18, 2026
• 01.08.2026 - RenovoRx To Announce Promising New Clinical Data Using its TAMP™ Therapy Platform in an Abstract to be Presented at ASCO GI 2026
• 12.11.2025 - RenovoRx Announces Acceptance of Clinical Data Abstract at the ASCO Gastrointestinal Cancers Symposium 2026
• 12.01.2025 - RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9th

Recent Filings

• 02.06.2026 - 8-K Current report
• 02.06.2026 - EX-99.1 EX-99.1
• 01.30.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 01.22.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.05.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.02.2026 - 8-K Current report
• 01.02.2026 - 4 Statement of changes in beneficial ownership of securities
• 12.22.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.17.2025 - 4 Statement of changes in beneficial ownership of securities